We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Split Panel Recommends Adasuve With Changes to REMS, Dosing
Split Panel Recommends Adasuve With Changes to REMS, Dosing
December 16, 2011
A closely divided FDA advisory panel has recommended that the agency approve Alexza Pharmaceuticals’ NDA for Adasuve to treat agitation in adults with schizophrenia or bipolar disorder, but approval should be based on a much lower dose than recommended by the sponsor and a much stricter risk evaluation and mitigation strategy (REMS).